《藍籌業績》石藥(01093.HK)全年純利51.6億人幣升38.9% 派末期息9港仙
石藥集團(01093.HK)公布截至去年12月底止全年業績,營業額249.42億元人民幣(下同),按年升12.8%。純利51.6億元,按年升38.9%;每股盈利43.16分。派末期息9港仙。
期內,毛利為186.85億元,按年升17.4%;毛利率升2.9個百分點至74.9%。按業務劃分,去年成藥收入204.05億元,按年升13.8%;維生素C收入18.59億元,跌3.2%;抗生素收入升30.4%至13.73億元。
於去年,研發費用為28.9億元,按年增加44.5%,約佔成藥業務收入的14.2%。
集團指,目前在研項目約300項,其中小分子創新藥40餘項、大分子創新藥40餘項,新型製劑20餘項,主要聚焦在腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染治療領域。目前有30個藥品處於註冊審評待批階段,41個產品正在開展臨床試驗(包括30個創新藥以及11個新型製劑),8個產品正在進行生物等效試驗,以及2個產品待批臨床批件。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.